Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology recommended by NICE. These cookies remember information that ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative devices and digital therapeutics transform patient care as ...

This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...

This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital ...

This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

Our mission is to get the best treatment and care to patients fast at value to the taxpayer. Through this forward view, we will highlight the topics we are focusing on, and that matter most to you in ...

This guidance has been updated and replaced by NICE guideline NG226. Back to top ...